VERA is trading 5.7% up at $44.88 in pre-market, extending a strong multi-day rally fueled by ongoing positive sentiment around its lead drug, atacicept.
- Recent gains follow supportive analyst views regarding the FDA timeline and PDUFA date, though no fresh company-specific news has been released this morning.
- The stock appears to be benefiting from a generally positive broader market tone as it continues its upward momentum from last week.